Diagnostic Delays and Stage Migration
Timely diagnosis remains one of the most consequential and modifiable determinants of melanoma outcome. Lower socioeconomic status (SES) is independently associated with advanced stage at presentation 13, reflecting well-documented barriers including reduced healthcare access, limited skin cancer awareness, geographic isolation, and scarcity of dermatologic resources in under-resourced settings. The 2021 Global Burden of Disease analysis confirmed that lower-income regions bear disproportionately high mortality-to-incidence ratios despite lower absolute incidence, underscoring the survival cost of delayed presentation 14.
Although emerging technologies—AI-assisted dermoscopy, total body photography, and digital triage—hold promise for earlier detection, real-world adoption data and evidence on their impact on recurrence or survival remain limited in the retrieved materials 23. The clinical stakes are significant: multiple trials illustrate that earlier systemic integration translates directly into survival benefit. In NADINA, neoadjuvant ipilimumab plus nivolumab prior to surgery achieved 18-month event-free survival (EFS) of 80.8% versus 53.9% with upfront surgery followed by adjuvant nivolumab (HR 0.32) 26. Any diagnostic delay that advances stage at presentation or renders disease surgically unresectable forecloses access to these neoadjuvant pathways.
Initial Staging and Workup Gaps
Sentinel lymph node biopsy (SLNB) is endorsed across all major guidelines—NCCN (v1.2026), ESMO (2025), AAD, and CSCO (2025)—for melanomas exceeding 1 mm Breslow thickness, with selective application for 0.8–1.0 mm tumors bearing high-risk features 146. SLNB provides critical prognostic information and, critically in the modern era, determines eligibility for adjuvant systemic therapy. However, real-world SLNB utilization is incompletely characterized. A National Cancer Database analysis of 68,933 patients documented a dramatic decline in completion lymph node dissection (CLND) after positive SLNB, from 59% in 2012 to 12.6% in 2018, without clinically meaningful stage migration 17. This practice evolution aligns with phase III evidence from MSLT-II and DeCOG-SLT showing that CLND confers no overall survival (OS) benefit over observation with close ultrasound follow-up in patients with micrometastatic sentinel nodes 15. Nevertheless, CLND omission may underestimate nodal burden in a subset of patients (SLNB+CLND patients more often had N classification >N1a: 36.8% vs. 19.3%) 17, with potential implications for prognostic counseling and adjuvant therapy intensity decisions.
A separate and underappreciated gap involves technical variability in SLNB pathologic processing and IHC interpretation, which may result in inconsistent nodal staging across institutions 22. Standardization of sectioning protocols and reporting criteria is an unmet need. Similarly, suboptimal biopsy technique (shave vs. punch vs. excisional) can compromise Breslow thickness measurement and mitotic rate assessment, leading to understaging and missed SLNB candidacy 25.
Molecular testing for BRAF V600E/K, NRAS, and KIT mutations is mandated by NCCN, ESMO, and CSCO before treatment initiation 14. In Chinese cohorts, BRAF V600E rates are 25.9%, KIT mutations 10.8%, and NRAS approximately 20% in non-chronic sun-damaged subtypes—each conferring distinct prognostic and therapeutic implications [citation:ClinicalGuidelineSearch]. In BRAF-mutant stage III disease, access to confirmed mutational status gates adjuvant dabrafenib plus trametinib, which yields 5-year RFS of 52% versus 36% (HR 0.52) and DMFS HR 0.56 versus placebo in COMBI-AD 26. Delays in reflex molecular testing or failure to integrate results before the multidisciplinary tumor board directly compromise timely adjuvant decision-making.
Undertreatment and Access to Effective Therapy
Real-world adjuvant therapy uptake patterns diverge substantially from guideline-concordant recommendations. A propensity-matched Dutch Melanoma Treatment Registry analysis (n=646 stage III BRAF-mutant patients, 2018–2021) found that comorbidities and geographic region—rather than tumor characteristics—drove adjuvant therapy selection, with BRAF/MEK inhibitors preferentially used in patients with autoimmune or musculoskeletal conditions (20.2% vs. 3.4% for anti-PD-1, p<0.01) 7. This reflects clinically reasonable immunotherapy avoidance in autoimmune disease, but may represent a quality gap when driven by geography or practice preference.
Critically, real-world anti-PD-1 efficacy is substantially lower in Asian populations with acral melanoma. A Fudan University retrospective cohort (n=93 stage III BRAF V600E-mutant patients, 2017–2021) found that anti-PD-1 monotherapy yielded 1-year RFS of only 58.1% versus 81.7% for dabrafenib plus trametinib (D+T) (p=0.032), with recurrence rates of 56% versus 16% 8. These findings likely reflect lower tumor-infiltrating lymphocytes (TIL) and tumor mutational burden (TMB) in acral lentiginous melanoma—consistent with KEYNOTE-151 data showing only ~15% ORR in Chinese acral/mucosal subtypes versus 54% in Caucasian cohorts 8. In Western guidelines uniformly recommending anti-PD-1 for stage III melanoma, this geographic disparity represents a critical unmet need requiring adaptive regional algorithms.
The emergence of neoadjuvant immunotherapy adds another dimension of practice readiness. NADINA's neoadjuvant ipilimumab plus nivolumab strategy achieved an 18-month EFS of 80.8% (HR 0.32 vs. adjuvant nivolumab alone) and is now incorporated into ESMO and NCCN recommendations for resectable stage IIIB–IV disease 426. Centers lacking rapid surgical-medical oncology coordination infrastructure, or multidisciplinary pathologic response assessment pathways, are unlikely to operationalize this approach—forfeiting substantial EFS benefit compared with the adjuvant-only standard.
Treatment Adherence, Persistence, and Toxicity Management
A consistent and concerning finding across real-world registries is premature treatment discontinuation, which likely attenuates the RFS and OS advantages observed in trials. In the Dutch registry, 45.6% of BRAF/MEK-treated and 61.0% of anti-PD-1-treated patients discontinued adjuvant therapy prematurely—driven not only by toxicity but also by patient preference and physician decision 7. The German-language multicenter cohort (n=1,198) similarly found recorded AE rates well below trial-reported levels (Grade ≥3: 11.5% real-world vs. 41% in COMBI-AD) 10, suggesting systematic underreporting and potential under-management of toxicity.
The Spanish DESCRIBE-AD real-world study of adjuvant dabrafenib plus trametinib (n=65) reported Grade 3–4 TRAEs in 21.5% of patients—again lower than the 41% in COMBI-AD—with treatment discontinuation due to toxicity in only 9% 21. Twelve-month RFS was 95.3%, suggesting that proactive dose management may preserve efficacy without sacrificing tolerability. Conversely, in the German cohort, anti-PD-1-treated patients who developed irAEs had significantly lower recurrence rates than those without (HR 0.578, p=0.001), positioning irAEs as a potential biomarker of immunotherapy engagement 10—an insight that argues for active toxicity monitoring rather than preemptive therapy de-escalation.
The neoadjuvant setting demands heightened irAE readiness: in NADINA, Grade ≥3 TRAEs occurred in 29.7% of patients receiving ipilimumab plus nivolumab preoperatively versus 14.7% with adjuvant nivolumab 26. Multidisciplinary irAE management pathways—co-managing endocrinology, gastroenterology, and pulmonology—are prerequisites for maintaining curative-intent treatment trajectories in this setting.
Surveillance, Monitoring, and Survivorship
Current guidelines stratify surveillance intensity by risk: stage IIB–IV patients receive imaging (CT, ultrasound, MRI) every 3–6 months for 2 years, then annually, while early-stage patients require only clinical examination [citation:ClinicalGuidelineSearch]4. Real-world adherence to these imaging schedules and the timeliness of recurrence detection are not well-characterized in the retrieved materials 26.
Circulating tumor DNA (ctDNA) as a minimal residual disease (MRD) and relapse-risk biomarker represents a promising but under-implemented innovation. KEYNOTE-942 data indicate that the neoantigen vaccine mRNA-4157 plus pembrolizumab reduced recurrence/death risk by 49% (HR 0.510; 2.5-year RFS 74.8% vs. 55.6%) and distant metastasis risk by 62% (HR 0.384) 26; however, ctDNA-guided surveillance frameworks remain at an early implementation stage with limited real-world adoption data 2326.
| Gap Domain | Key Real-World Finding | Outcome Impact |
|---|---|---|
| Stage at diagnosis | Lower SES linked to advanced stage 13 | Reduced adjuvant eligibility, worse DSS |
| SLNB/staging variability | CLND declining (12.6% in 2018); IHC interpretation inconsistent 1722 | Understaging in ~5–10% SLNB-positive patients |
| Molecular testing delays | Testing access gates BRAF/MEK adjuvant therapy | Forfeits RFS HR 0.52 (COMBI-AD) 26 |
| Anti-PD-1 in Asian acral melanoma | 1-yr RFS 58.1% vs. 81.7% for D+T (p=0.032) 8 | Substantial underperformance vs. Western benchmarks |
| Neoadjuvant adoption | Limited center readiness; NADINA EFS 80.8% vs. 53.9% (HR 0.32) 26 | Forfeited EFS benefit without workflows |
| Treatment discontinuation | 45–61% premature discontinuation in real-world 7 | Likely attenuates RFS/OS trial benefits |
| ctDNA surveillance | Limited clinical implementation 23 | Early relapse detection benefit unrealized |
| Health equity | SES and non-Caucasian ethnicity linked to delays, advanced stage 1314 | Downstream effects on treatment eligibility and survival |
Health Equity and Modifiable Priorities
Persistent disparities by SES, race/ethnicity, geography, and healthcare system capacity affect every node of the melanoma care continuum 131416. Underrepresentation of non-Caucasian and elderly populations in pivotal ICI trials limits the generalizability of guideline recommendations—a gap exemplified by the differential efficacy of anti-PD-1 therapy in acral melanoma subtypes prevalent in Asian populations 816. Most actionable near-term priorities include: (1) reflex molecular testing at diagnosis of stage II–III disease integrated before multidisciplinary tumor board; (2) standardized SLNB processing and IHC reporting protocols; (3) institutionalized neoadjuvant workflows for resectable macroscopic stage III disease aligned with NADINA benchmarks; (4) irAE co-management pathways to sustain dose intensity for dual checkpoint and neoadjuvant combinations; (5) referral networks for TIL therapy (ORR 31.4%, median DOR 36.5 months in anti-PD-1-refractory disease) and oncolytic immunotherapy programs 26; and (6) prospective real-world studies specifically designed to characterize outcomes in underrepresented populations, closing the evidence gap between trial-derived recommendations and diverse clinical practice.